Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is on track to launch its revolutionary psilocybin-based treatment for treatment-resistant depression (TRD) in the first half of 2027 following the completion of its rolling NDA submission in the fourth quarter of 2026. The company has demonstrated strong clinical data for its TRD program with promising results from its Phase 3 trials, and is also pursuing research and development for potential treatments for other mental health disorders such as PTSD, with a current late-stage study underway. The company has a favorable label and expects a similar REMS to the existing one for Johnson & Johnson's SPRAVATO, positioning it well in the competitive landscape.

Bears say

Compass Pathways is in a niche market, and while its focus on developing therapies for mental health conditions is commendable, it may face challenges in gaining widespread market acceptance for its treatment. Despite having a proprietary formulation with Breakthrough Therapy designation and Innovative Licensing and Access Pathway designation, the company will likely face high development and marketing costs in order to succeed. Additionally, its limited track record and lack of revenue may make it a risky investment.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.